EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes

Jennifer S Lees iD, Stephen J H Dobbin, Benjamin M P Elyan, David F Gilmour, Laurie P Tomlinson iD, Ninian N Lang, Patrick B Mark iD

Nephrology Dialysis Transplantation · 2023

DOI: 10.1093/ndt/gfac305 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Jennifer S Lees und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Sciences, University of Glasgow, Glasgow, UK. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Hypertension. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chief Scientist Office, British Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vascular endothelial growth factor inhibitors (VEGFis) have transformed the treatment of many retinal diseases, including diabetic maculopathy. Increasing evidence supports systemic absorption of intravitreal VEGFi and development of significant cardiorenal side effects.

Methods

We conducted a systematic review and meta-analysis (PROSPERO: CRD42020189037) of randomised controlled trials of intravitreal VEGFi treatments (bevacizumab, ranibizumab and aflibercept) for any eye disease. Outcomes of interest were cardiorenal side effects (hypertension, proteinuria, kidney function decline and heart failure). Fixed effects meta-analyses were conducted where possible.

Results

There were 78 trials (81 comparisons; 13 175 participants) that met the criteria for inclusion: 47% were trials in diabetic eye disease. Hypertension (29 trials; 8570 participants) was equally common in VEGFi and control groups {7.3 versus 5.4%; relative risk [RR] 1.08 [95% confidence interval (CI) 0.91–1.28]}. New or worsening heart failure (10 trials; 3384 participants) had a similar incidence in VEGFi and control groups [RR 1.03 (95% CI 0.70–1.51)]. Proteinuria (5 trials; 1902 participants) was detectable in some VEGFi-treated participants (0.2%) but not controls [0.0%; RR 4.43 (95% CI 0.49–40.0)]. Kidney function decline (9 trials; 3471 participants) was similar in VEGFi and control groups. In participants with diabetic eye disease, the risk of all-cause mortality was higher in VEGFi-treated participants [RR 1.62 (95% CI 1.04–2.46)].

Conclusion

In trials of intravitreal VEGFi, we did not identify an increased risk of cardiorenal outcomes, although these outcomes were reported in only a minority of cases. There was an increased risk of death in VEGFi-treated participants with diabetic eye disease. Additional scrutiny of post-licensing observational data may improve the recognition of safety concerns in VEGFi-treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyHypertensionHumansVascular Endothelial Growth Factor AAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorProteinuria

Stichwörter der Autor:innen

CKDdiabetes mellitushypertensionproteinuriasystematic review

Substanzen

Vascular Endothelial Growth Factor AAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth Factor

Autor:innen und Institutionen

  • School of Cardiovascular and Metabolic Health, College of Medical and Veterinary Sciences, University of Glasgow, Glasgow, UK.
  • Glasgow Centre for Ophthalmic Research, NHS Greater Glasgow and Clyde, Glasgow, UK.
  • Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.

ORCID-Profile: Jennifer S Lees, Laurie P Tomlinson, Patrick B Mark

Förderung

  • Chief Scientist Office
  • British Heart Foundation

Zitieren

APA

Lees, J. S., Dobbin, S. J. H., Elyan, B. M. P., Gilmour, D. F., Tomlinson, L. P., Lang, N. N., & Mark, P. B. (2023). A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac305

Vancouver

Lees JS, Dobbin SJH, Elyan BMP, Gilmour DF, Tomlinson LP, Lang NN, et al. A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac305

BibTeX
@article{Lees2023,
  author = {Lees, Jennifer S and Dobbin, Stephen J H and Elyan, Benjamin M P and Gilmour, David F and Tomlinson, Laurie P and Lang, Ninian N and Mark, Patrick B},
  title = {A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  doi = {10.1093/ndt/gfac305}
}
Kostenlos starten →